Clinical Trials Logo

Clinical Trial Summary

This study; It will be done in order to compare the quality of life and physical activity levels of physically disabled individuals who continue and do not continue rehabilitation during COVID-19. International Physical Activity Questionnaire Short Form (IPAQ) and The Quality of Life Scale for Children (PedsQL) questionnaire will be applied.


Clinical Trial Description

Studies on COVID-19, which is spreading rapidly all over the world, show that the pediatric population is less affected than the adult and elderly population. Respiratory complications are the leading cause of death in the chronic neuropediatric population. During the pandemic, rehabilitation staff such as physiotherapists are at risk of transmission and therefore their activities should be suspended. For this reason, a 3-month quarantine was applied for individuals who went to special education and rehabilitation in our country from March 2020 to June 2020, and face-to-face sessions could not be continued in rehabilitation. The negative effects of social isolation in children and adolescents during the pandemic affect mental and physical health. Studies show the importance of physical rehabilitation for pediatric patients with chronic neurological disorders. Rehabilitation is not continuous; It may cause soft tissue contractures, bone deformities, decline in motor functions, dysphagia and respiratory difficulties, among other complications. Pediatric patients with neurological disorders may also experience decline in motor function. Although it is known that rehabilitation services have started again with the strict implementation of social distance and hygiene rules in our country as of June 2020; while some of the physically disabled individuals continue their rehabilitation, those who do not continue with rehabilitation are at a considerable level. Therefore, our study; it will be made in order to compare the quality of life and physical activity levels of physically disabled individuals who continue and do not continue rehabilitation during COVID-19. Following the approval of the ethics committee, a questionnaire will be applied to 18 children with physical disabilities who continue rehabilitation and 18 children with physical disabilities but who do not continue rehabilitation during COVID-19. The study will start with the approval of the ethics committee and is planned to be completed in October 2021, within 6 months. The gross motor levels of the children who meet the inclusion criteria and whose families voluntarily accept to participate in the study are determined according to KMFSS, International Physical Activity Questionnaire Short Form (IPAQ) and Quality of Life Scale for Children (PedsQL) questionnaires will be applied to both children who continue special education and rehabilitation during COVID-19 and children who are not. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04900402
Study type Observational
Source Saglik Bilimleri Universitesi
Contact
Status Completed
Phase
Start date May 18, 2021
Completion date October 2, 2021

See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3